RT Journal Article
SR Electronic
T1 The dichotomous and incomplete adaptive immunity in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.05.20187435
DO 10.1101/2020.09.05.20187435
A1 Leiqiong Gao
A1 Jing Zhou
A1 Sen Yang
A1 Xiangyu Chen
A1 Yang Yang
A1 Ren Li
A1 Zhiwei Pan
A1 Jing Zhao
A1 Zhirong Li
A1 Qizhao Huang
A1 Jianfang Tang
A1 Li Hu
A1 Pinghuang Liu
A1 Guozhong Zhang
A1 Yaokai Chen
A1 Lilin Ye
YR 2020
UL http://medrxiv.org/content/early/2020/09/07/2020.09.05.20187435.abstract
AB The adaptive immunity that protects patients from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is not well characterized. In particular, the asymptomatic patients have been found to induce weak and transient SARS-CoV-2 antibody responses, but the underlying mechanisms remain unknown; meanwhile, the protective immunity that guide the recovery of these asymptomatic patients is also not well studied. Here, we characterized SARS-CoV-2-specific B-cell and T-cell responses in 10 asymptomatic patients and 49 patients with other disease severity (mild, n = 10, moderate, n = 32, severe, n = 7) and found that asymptomatic or mild symptomatic patients failed to mount virus-specific germinal center (GC) B cell responses that result in robust and long-term humoral immunity, assessed by GC response indicators including follicular helper T (TFH) cell and memory B cell responses as well as serum CXCL13 levels. Alternatively, these patients mounted potent virus-specific TH1 and CD8+ T cell responses. In sharp contrast, patients of moderate or severe disease induced vigorous virus-specific GC B cell responses and associated TFH responses; however, the virus-specific TH1 and CD8+ T cells were minimally induced in these patients. These results therefore uncovered the protective immunity in COVID-19 patients and revealed the strikingly dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity, providing important insights into rational design of COVID-19 vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Science and Technology Major Project (No. 2017ZX10202102-006-002 to L.Y.), the National Natural Science Fund for Distinguished Young Scholars (No. 31825011 to L.Y.), the National Key Research Development Plan (No.2016YFA0502202 to L. Ye) and the Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and Control (No. cstc2020jscx-2 to L.Y.; No. cstc2020jscx-fyzx0074 to Y.C.; ocstc2020jscx-fyzx0135 to Y.C.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received IRB approvals at Chongqing Public Health Medical Center (2020-023-01-KY).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in medRxiv